U3-1402
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer, Advanced Breast Cancer
Trial Timeline
May 11, 2021 → Apr 11, 2030
NCT ID
NCT04965766About U3-1402
U3-1402 is a phase 2 stage product being developed by Daiichi Sankyo for Metastatic Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04965766. Target conditions include Metastatic Breast Cancer, Advanced Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04965766 | Phase 2 | Recruiting |
| NCT04699630 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic Breast Cancer